Specialty Natural Products Public Company LimitedSET: SNPS🇹🇭 TH

MD&A · 2025

Overview of Operations

Overview of Operations

Executive Overview

“Quality Growth and Operational Excellence”

In 2025, the Group achieved outstanding operating performance, characterized by strong revenue growth and a significant expansion in profit margins. The Group commenced the strategic transition toward higher value-added products, resulting in a 43.91% increase in net profit, exceeding the 20.44% growth in revenue. This performance demonstrates the Group ability to scale its business efficiently. The Group generated total revenue of THB 571.70 million, increasing from the previous year, and recorded net profit of THB 109.82 million, growing at a rate significantly higher than revenue growth. These results reflect management’s capability to execute a quality growth strategy alongside effective cost and expense management, particularly the reduction in selling and administrative expenses despite continued business expansion.

The fourth quarter of 2025 marked a new record high for both revenue and net profit since the Group establishment. Revenue amounted to THB 155.08 million, representing a 26.25% increase year-on-year, while net profit reached THB 33.46 million, increasing by 35.47% year-on-year. This performance was driven by the execution of product strategies, disciplined cost management, and continuous improvements in the Group’s operating structure throughout the year.

Operating Results & Financial Condition

Operating Results & Profitability

Operating Results for the Ended December 31, 2025

  • Revenue Growth and Business Structure

The Group continues to focus on its transition toward a high-value integrated business model. As a result, in the fourth quarter of 2025, the Group recorded sales and service revenue of THB 155.08 million, increasing from THB 122.84 million in the same period of the previous year.This growth was primarily supported by continued expansion in revenue from standardized herbal extract products (API), as well as revenue from products under the Group’s own brands (OBM), driven by the launch of new products in prior periods and the initial realization of marketing and distribution strategies.

  • Gross Profit and Margin Management

In the fourth quarter of 2025, the Group’s gross profit remained at a level comparable to that of the same period last year, despite pressures from a shift in revenue mix toward products with moderate margins and increases in certain raw material costs during the year. Nevertheless, these results reflect the Group’s ability to maintain overall margin levels through effective cost management. Management has continued to implement cost-control measures, including supplier negotiations and pricing strategy adjustments, to support the preservation of profitability in subsequent periods.

  • Selling Expenses

Selling expenses in the fourth quarter of 2025 remained higher compared to the same period of the previous year. This was primarily attributable to ongoing marketing and sales activities aimed at strengthening customer relationships and expanding the order base across both the standardized herbal extract (API) segment and the original design manufacturing (ODM) segment. Key activities included participation in trade exhibitions, commercial events, and promotional campaigns. Management considers these initiatives to be strategic investments designed to create new business opportunities and support medium-term revenue growth.

However, when measured as a proportion of sales, selling expenses in the fourth quarter of 2025 declined to 3.86%, compared with 4.76% in the same period of the previous year. This improvement reflects enhanced efficiency in managing selling expenses and the Group’s ability to generate revenue from marketing activities at an appropriate cost level. The Group continues to closely monitor and evaluate the return on investment of its sales and marketing initiatives to ensure that such expenditures generate long-term value and do not exert undue pressure on the Group’s overall profitability.

Asset Management Capability

  • Total Assets

As of 31 December 2025, the Group had total assets of THB 1,024.68 million, representing an increase of THB 36.98 million, or 3.74%, compared with total assets as of 31 December 2024. The increase was primarily attributable to higher trade receivables and other current receivables, as well as other current assets.

  • Total Liabilities

As of 31 December 2025, the Group’s total liabilities amounted to THB 99.46 million, increasing by THB 8.44 million, or 9.27%, compared with total liabilities as of 31 December 2024. The increase was mainly due to higher accrued corporate income tax. Nevertheless, the Group’s liabilities remained at a low level, reflecting a strong capital structure and the ability to support ongoing operations and future investments.

  • Shareholders’ Equity

As of 31 December 2025, the Group’s shareholders’ equity amounted to THB 925.22 million, representing an increase of THB 28.54 million, or 3.18%, compared with shareholders’ equity as of

31 December 2024. The increase was primarily attributable to the growth in retained earnings. The Group shareholders’ equity remained at a high level, reflecting a solid financial position, the ability to generate returns from operations, and the balanced allocation of benefits to shareholders while maintaining long-term growth capacity.

Debt Obligations & Off-Balance-Sheet Management

  • Credit Terms and Collection Period

The Group grants credit terms to its customers ranging from 30 to 60 days, depending on the nature of sales and services. The majority of the Group’s customers are granted credit terms of 30 days. As of 31 December 2025, the Group’s average collection period was 81 days, representing an increase of 18 days from the average collection period of 63 days as of 31 December 2024. The increase was primarily attributable to higher trade receivables, in line with revenue growth and changes in customer mix, with certain customer groups operating under longer payment cycles.

Management places strong emphasis on credit risk management and working capital control. This includes close monitoring of receivable status, the establishment of credit terms appropriate to business characteristics, and intensified collection efforts for customer groups with longer payment cycles. These measures are aimed at ensuring that the extended collection period does not adversely affect the Group’s liquidity position or its long-term operating capability.

  • Executive Summary

The Group is well positioned to capture opportunities arising from global health trends, supported by growing demand for natural products in the pharmaceutical, food, and cosmetics industries, as well as the ongoing relocation of manufacturing bases to Southeast Asia. The Group operates under a high-value integrated business model, combining bioscience expertise with the application of digital technologies to create product differentiation, enhance value across the value chain, and strengthen long-term competitiveness.

In 2025, the Group delivered strong operating performance, generating total revenue of THB 571.70 million and net profit of THB 109.82 million. These results reflect the effectiveness of revenue expansion alongside disciplined cost and expense management. The fourth quarter of 2025 marked a new record high for both revenue and net profit, demonstrating tangible outcomes from the strategies implemented throughout the year.

Growth was primarily driven by continued expansion in standardized herbal extract products (API), together with the expansion of distribution channels for the Group’s own-brand products (OBM). Meanwhile, the original design manufacturing (ODM) business continued to provide a stable revenue base and consistent cash flow support.

Material & Related-Party Transactions

The Company considers the relationship between related individuals or entities for each transaction. The Company prioritizes the substance of the relationship over its legal form.

In 2025, the Company had no significant related party transactions, based on the value of the transactions. The total value of related party transactions, as disclosed in the financial statements as of December 31, 2025, did not include any transactions exceeding 10 percent of the total revenue for 2025.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

The company plans to invest in developing and extending research outcomes into commercial production and distribution for the "artificial saliva gel" product, aimed at alleviating dry mouth symptoms in cancer patients, especially those from underprivileged backgrounds. This may impact the company's financial position and operational performance in the following key areas:

1. Impact on Investment and Cash Flow

  • Requires additional investment budget in research and development (R&D), stability testing, safety testing, and product registration with relevant authorities.

  • There may be costs associated with upgrading production lines, machinery, or quality control systems.

  • This will lead to increased short-term expenses and may affect operating cash flow.

2. Regulatory and Registration Risks

  • The classification of the product (medical device / cosmeceutical / health product) may affect the procedures, duration, and costs of obtaining permits.

  • If the approval process is delayed, revenue recognition may be postponed.

3. Image and ESG Opportunities (Strategic & ESG Opportunity)

  • The project aligns with ESG policies and social enterprise operations.

  • Helps enhance the organization's image in terms of social responsibility.

  • May increase opportunities for accessing green funding sources or collaborating with government agencies and research institutions.

4. Impact on Medium-to-Long-Term Performance

  • If the product is successful, the market can be expanded to private hospitals or OTC channels.

  • May be further developed into other Oral Care Medical Grade products.

Contents